Managing anemia in for-profit dialysis chains: When ethics and business conflict

Seminars in Dialysis

Volumn 22, Issue 1, 2009, Pages 18-21

  Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COST; ECONOMICS; HUMAN; IRON DEFICIENCY ANEMIA; METABOLISM; REIMBURSEMENT; UNITED STATES;

ANEMIA, IRON-DEFICIENCY; DRUG COSTS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 60349128720     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2008.00531.x     Document Type: Article

References (20)

1. Eckardt KU : Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant 20 (Suppl. 6 vi16 vi20, 2005
2. Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ : DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 22 : 175 180, 2004
3. Port FK, Pisoni RL, Bommer J, Locatelli F, Jadoul M, Eknoyan G, Kurokawa K, Canaud BJ, Finley MP, Young EW : Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 1 : 246 255, 2006
4. Dialysis Facility Compare. Available at http://www.medicare.gov/Dialysis/ Include/DataSection/Questions/SearchCriteria.asp?version=default&browser= IE%7C6%7CWinXP&language=English&defaultstatus=0&pagelist=Home, accessed May 19, 2008
5. System, URD : USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD : National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
6. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584 590, 1998
7. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071 2084, 2006
8. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085 2098, 2006
9. Coyne DW : From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy. Semin Dial 21 : 212 216, 2008
10. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K : Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 : 1181 1191, 2006
11. KDOQI : Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 : S11 S145, 2006
12. Da Vita 1: DaVita Corporation : 2007 Annual Report, Form K-10, Securities and Exchange Commission. Flushing, MI : DaVita Corporation, 2008
13. Fresenius Medical Care : Annual Report, Form 20-F, Securities and Exchange Commission. Waltham, MA : Fresenius Medical Care, 2007
14. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA : Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 : 1667 1674, 2007
15. Coyne DW : Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2 : 3 7, 2007 discussion 13-14
16. Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, Moist L, Steinberg E, Walker R, Wanner C, Lameire N, Eknoyan G : Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70 : 2058 2065, 2006
17. Van Wyck DB, Eckardt KU, Uhlig K, Rocco MV, Levin A : Response to "Influence of Industry on Renal Guideline Development." Clin J Am Soc Nephrol 2 : 13 14, 2007
18. European Medicines Agency : Public Statement: Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. 2007
19. KDOQI : Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 : 471 530, 2007
20. Epogen (Epoetin alfa) Prescribing information. Thousand Oaks, CA : Amgen, Inc., 2008. Available at http://www.epogen.com/professional/resources/ prescribing-information/pi.jsp